Similar articles

Abstract: The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has occasioned worldwide alarm. Globally, the number of reported confirmed cases has exceeded 84.3 million as of this writing (January 2, 2021). Since there are no targeted therapies for COVID-19, the current focus is the repurposing of drugs approved for other uses. In some clinical trials, antiviral drugs such as remdesivir (Grein et al., 2020), lopinavir/ritonavir (LPV/r) (Cao et al., 2020), chloroquine (Gao et al., 2020), hydroxychloroquine (Gautret et al., 2020), arbidol (Wang et al., 2020), and favipiravir (Cai et al., 2020b) have shown efficacy in COVID-19 patients. LPV/r combined with arbidol, which is the basic regimen in some regional hospitals in China including Zhejiiang Province, has shown antiviral effects in COVID-19 patients (Guo et al., 2020; Xu et al., 2020). A retrospective cohort study also reported that this combination therapy showed better efficacy than LPV/r alone for the treatment of COVID-19 patients (Deng et al., 2020).

COVID-19潜在治疗药物洛匹那韦/利托那韦和阿比多尔在大鼠体内的药代动力学相互作用

[1]CaiQX, HuangDL, YuH, et al., 2020a. COVID-19: abnormal liver function tests. J Hepatol, 73(3):566-574.

[2]CaiQX, YangMH, LiuDJ, et al., 2020b. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing), 6(10):1192-1198.

[3]CaoB, WangYM, WenDN, et al., 2020. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med, 382(19):1787-1799.

[4]DengLS, LiCN, ZengQ, et al., 2020. Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study. J Infect, 81(1):E1-E5.

[5]GaoJJ, TianZX, YangX, 2020. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends, 14(1):72-73.

[6]GautretP, LagierJC, ParolaP, et al., 2020. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents, 56(1):105949.

[7]GreinJ, OhmagariN, ShinD, et al., 2020. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med, 382(24):2327-2336.

[8]GuoYZ, XuKJ, LiYT, et al., 2020. Safety of protease inhibitors and Arbidol for SARS-CoV-2 pneumonia in Zhejiang Province, China. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 21(12):948-954.

[9]JiangSP, WangRR, LiL, et al., 2020. Liver injury in critically ill and non-critically ill COVID-19 patients: a multicenter, retrospective, observational study. Front Med (Lausanne), 7:347.

[10]JullienV, UrienS, HirtD, et al., 2006. Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years. Antimicrob Agents Chemother, 50(11):3548-3555.

[11]LiverTox, 2012. Clinical and research information on drug-induced liver injury: protease inhibitors (HIV). Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. https://www.ncbi.nlm.nih.gov/books/NBK548893

[12]OfotokunI, ChuckSK, BinongoJN, et al., 2007. Lopinavir/ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy. J Clin Pharmacol, 47(8):970-977.

[13]UmehOC, CurrierJS, ParkJG, et al., 2011. Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men. J Clin Pharmacol, 51(12):1665-1673.

[14]WangZL, YangBH, LiQW, et al., 2020. Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis, 71(15):769-777.

[15]XuKJ, CaiHL, ShenYH, et al., 2020. Management of COVID-19: the Zhejiang experience. J Zhejiang Univ (Med Sci), 49(2):147-157 (in Chinese).

[16]ZhangC, ShiL, WangFS, 2020. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol, 5(5):428-430.